Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes

被引:8
|
作者
Cheong, Hyun Sub [2 ]
Kim, Hae Deun [1 ]
Na, Han Sung [1 ]
Kim, Ji On [2 ]
Kim, Lyoung Hyo [2 ]
Kim, Seung Hee [1 ]
Bae, Joon Seol [3 ]
Chung, Myeon Woo [1 ]
Shin, Hyoung Doo [2 ,3 ]
机构
[1] Natl Inst Food & Drug Safety Evaluat, Dept Toxicol Evaluat & Res, Cheongwon Gun 363951, Chungcheongbuk, South Korea
[2] SNP Genet Inc, Dept Genet Epidemiol, Seoul, South Korea
[3] Sogang Univ, Dept Life Sci, Seoul 121742, South Korea
关键词
ethnic diversity; pharmacogenetics; solute carrier family gene; SINGLE NUCLEOTIDE POLYMORPHISMS; ORGANIC CATION TRANSPORTER; DIFFERENTIAL RECOGNITION; PEPTIDE TRANSPORTERS; METFORMIN; VARIANTS; OCT1; IDENTIFICATION; EVOLUTIONARY; EXPRESSION;
D O I
10.1038/jhg.2011.77
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
A growing list of membrane-spanning proteins involved in the transport of a large variety of drugs has been recognized and characterized to include peptide and organic anion/cation transporters. Given such an important role of transporter genes in drug disposition process, the role of single-nucleotide polymorphisms (SNPs) in such transporters as potential determinants of interindividual variability in drug disposition and pharmacological response has been investigated. To define the distribution of transporter gene SNPs across ethnic groups, we screened 450 DNAs in cohorts of 250 Korean, 50 Han Chinese, 50 Japanese, 50 African-American and 50 European-American ancestries for 64 SNPs in four transporter genes encoding proteins of the solute carrier family (SLC15A2, SLC22A1, SLC22A2 and SLC22A6). Of the 64 SNPs, 19 were core pharmacogenetic variants and 45 were HapMap tagging SNPs. Polymorphisms were genotyped using the golden gate genotyping assay. After genetic variability, haplotype structures and ethnic diversity were analyzed, we observed that the distributions of SNPs in a Korean population were similar to other Asian groups (Chinese and Japanese), and significantly different from African-American and European-American cohorts. Findings from this study would be valuable for further researches, including pharmacogenetic studies for drug responses. Journal of Human Genetics (2011) 56, 666-670; doi: 10.1038/jhg.2011.77; published online 28 July 2011
引用
收藏
页码:666 / 670
页数:5
相关论文
共 50 条
  • [1] Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes
    Hyun Sub Cheong
    Hae Deun Kim
    Han Sung Na
    Ji On Kim
    Lyoung Hyo Kim
    Seung Hee Kim
    Joon Seol Bae
    Myeon Woo Chung
    Hyoung Doo Shin
    [J]. Journal of Human Genetics, 2011, 56 : 666 - 670
  • [2] Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension
    Sallinen, Riitta
    Kaunisto, Mari A.
    Forsblom, Carol
    Thomas, Merlin
    Fagerudd, Johan
    Pettersson-Fernholm, Kim
    Groop, Per-Henrik
    Wessman, Maija
    [J]. ANNALS OF MEDICINE, 2010, 42 (04) : 296 - 304
  • [3] Association of SLC22A1, SLC22A2, SLC47A1, and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients
    Chen, Peixian
    Cao, Yumin
    Chen, Shenren
    Liu, Zhike
    Chen, Shiyi
    Guo, Yali
    [J]. BIOMEDICINES, 2022, 10 (10)
  • [4] Human Organic Cation Transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as Disposition Pathways for Fluoroquinolone Antimicrobials
    Mulgaonkar, Aditi
    Venitz, Juergen
    Gruendemann, Dirk
    Sweet, Douglas H.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) : 2705 - 2711
  • [5] Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro
    Moss, Darren M.
    Liptrott, Neill J.
    Curley, Paul
    Siccardi, Marco
    Back, David J.
    Owen, Andrew
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (11) : 5612 - 5618
  • [6] The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26
    Koehler, MR
    Wissinger, B
    Gorboulev, V
    Koepsell, H
    Schmid, M
    [J]. CYTOGENETICS AND CELL GENETICS, 1997, 79 (3-4): : 198 - 200
  • [7] Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels
    Al-Eitan, Laith N.
    Almomani, Basima A.
    Nassar, Ahmad M.
    Elsaqa, Barakat Z.
    Saadeh, Nesreen A.
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2019, 9 (01):
  • [8] Interaction of H2-antagonists with human organic cation transporters hOCT1 (SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
    Bourdet, DL
    Pritchard, JB
    Thakker, DR
    [J]. DRUG METABOLISM REVIEWS, 2004, 36 : 262 - 262
  • [9] Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin
    Yang, Jian
    Kalogerou, Maria
    Gallacher, John
    Sampson, Julian R.
    Shen, Ming Hong
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1479 - 1490
  • [10] Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
    Bourdet, DL
    Pritchard, JB
    Thakker, DR
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03): : 1288 - 1297